Jci_page_head_homepage_01 Jci_page_head_homepage_02
Erica Salvati, Carlo Leonetti, Angela Rizzo, Marco Scarsella, Marcella Mottolese, Rossella Galati, Isabella Sperduti, Malcolm F.G. Stevens, Maurizio D’Incalci, Maria Blasco, Giovanna Chiorino, Serge Bauwens, Béatrice Horard, Eric Gilson, Antonella Stoppacciaro, Gabriella Zupi, Annamaria Biroccio
Published in Volume 117, Issue 11
J Clin Invest. 2007; 117(11):3236–3247 doi:10.1172/JCI32461
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 1
RHPS4 induces phosphorylation of H2AX in transformed and tumor cells.

(A) Human transformed BJ-EHLT and M14 melanoma cells were treated with RHPS4 for 4 days. At the indicated times, cells were counted and the viability determined. The data represent the number of untreated (filled squares) and RHPS4-treated cells (open squares) during the growth in culture. The mean of 3 independent experiments with comparable results is shown. Error bars indicate SD. (B) Percentage of cells containing γ-H2AX foci (upper panel) and Western blot analysis (lower panel) of γ-H2AX in BJ-EHLT and M14 cells treated with RHPS4 for the indicated times. γ-H2AX foci were quantified using mouse mAbs and rabbit pAbs. On average, more than 200 cells were screened per time point in 3 independent experiments. Error bars indicate SD. The levels of H2A were used as loading control. (C) Representative immunofluorescence images of BJ-EHLT and M14 cells treated with RHPS4 for 8 hours. Original magnification, ×40.